Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2014', provides an overview of the Functional (Non Ulcer) Dyspepsia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Functional (Non Ulcer) Dyspepsia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Functional (Non Ulcer) Dyspepsia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Functional (Non Ulcer) Dyspepsia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Functional (Non Ulcer) Dyspepsia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Functional (Non Ulcer) Dyspepsia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Functional (Non Ulcer) Dyspepsia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Functional (Non Ulcer) Dyspepsia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Functional (Non Ulcer) Dyspepsia Overview 6
Therapeutics Development 7
Pipeline Products for Functional (Non Ulcer) Dyspepsia - Overview 7
Pipeline Products for Functional (Non Ulcer) Dyspepsia - Comparative Analysis 8
Functional (Non Ulcer) Dyspepsia - Therapeutics under Development by Companies 9
Functional (Non Ulcer) Dyspepsia - Therapeutics under Investigation by Universities/Institutes 10
Functional (Non Ulcer) Dyspepsia - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Functional (Non Ulcer) Dyspepsia - Products under Development by Companies 14
Functional (Non Ulcer) Dyspepsia - Products under Investigation by Universities/Institutes 15
Functional (Non Ulcer) Dyspepsia - Companies Involved in Therapeutics Development 16
Eisai Co., Ltd. 16
Zeria Pharmaceutical Co Ltd 17
Almirall, S.A. 18
Ironwood Pharmaceuticals, Inc. 19
Rottapharm SpA 20
RaQualia Pharma Inc. 21
Functional (Non Ulcer) Dyspepsia - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 29
cinitapride - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
acotiamide hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
dexloxiglumide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
rabeprazole sodium - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
IW-9179 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
RQ-00201894 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
RQ-00000010 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
5-BOIP - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Functional (Non Ulcer) Dyspepsia - Recent Pipeline Updates 39
Functional (Non Ulcer) Dyspepsia - Dormant Projects 42
Functional (Non Ulcer) Dyspepsia - Discontinued Products 43
Functional (Non Ulcer) Dyspepsia - Product Development Milestones 44
Featured News & Press Releases 44
Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia 44
Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products under Development for Functional (Non Ulcer) Dyspepsia, H2 2014 7
Number of Products under Development for Functional (Non Ulcer) Dyspepsia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Functional (Non Ulcer) Dyspepsia - Pipeline by Eisai Co., Ltd., H2 2014 16
Functional (Non Ulcer) Dyspepsia - Pipeline by Zeria Pharmaceutical Co Ltd, H2 2014 17
Functional (Non Ulcer) Dyspepsia - Pipeline by Almirall, S.A., H2 2014 18
Functional (Non Ulcer) Dyspepsia - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 19
Functional (Non Ulcer) Dyspepsia - Pipeline by Rottapharm SpA, H2 2014 20
Functional (Non Ulcer) Dyspepsia - Pipeline by RaQualia Pharma Inc., H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 24
Number of Products by Stage and Mechanism of Action, H2 2014 26
Number of Products by Stage and Route of Administration, H2 2014 27
Number of Products by Stage and Molecule Type, H2 2014 28
Functional (Non Ulcer) Dyspepsia Therapeutics - Recent Pipeline Updates, H2 2014 39
Functional (Non Ulcer) Dyspepsia - Dormant Projects, H2 2014 42
Functional (Non Ulcer) Dyspepsia - Discontinued Products, H2 2014 43